A Study of a Long-Acting r-Factor 7a (Factor VIIa) in Adult Men With Hemophilia A or B
Status:
Completed
Trial end date:
2018-09-01
Target enrollment:
Participant gender:
Summary
The purpose of the current Phase 1/2a single dose, dose-escalating study is to evaluate the
acute safety, pharmacokinetics (PK) and pharmacodynamics (PD) properties of MOD-5014 in adult
subjects with moderate/severe congenital hemophilia A or B. This will be a single-dose, open
label, dose-escalating study. Each dose cohort will be concluded by a safety review,
following which escalation to the next dose cohort will be approved.